Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML
© 2021. The Author(s)..
BACKGROUND: CPX-351 (United States: Vyxeos®; Europe: Vyxeos® Liposomal), a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio, is approved by the US FDA and the EMA for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes. In a pivotal phase 3 study that evaluated 309 patients aged 60 to 75 years with newly diagnosed high-risk/secondary acute myeloid leukemia, CPX-351 significantly improved median overall survival versus conventional 7 + 3 chemotherapy (cytarabine continuous infusion for 7 days plus daunorubicin for 3 days), with a comparable safety profile. A Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of the phase 3 study was performed to compare survival quality between patients receiving CPX-351 versus conventional 7 + 3 after 5 years of follow-up.
METHODS: Patients were randomized 1:1 between December 20, 2012 and November 11, 2014 to receive induction with CPX-351 or 7 + 3. Survival time for each patient was partitioned into 3 health states: TOX (time with any grade 3 or 4 toxicity or prior to remission), TWiST (time in remission without relapse or grade 3 or 4 toxicity), and REL (time after relapse). Within each treatment arm, Q-TWiST was calculated by adding the mean time spent in each health state weighted by its respective quality-of-life, represented by health utility. The relative Q-TWiST gain, calculated as the difference in Q-TWiST between treatment arms divided by the mean survival of the 7 + 3 control arm, was determined in order to evaluate results in the context of other Q-TWiST analyses.
RESULTS: The relative Q-TWiST gain with CPX-351 versus 7 + 3 was 53.6% in the base case scenario and 39.8% among responding patients. Across various sensitivity analyses, the relative Q-TWiST gains for CPX-351 ranged from 48.0 to 57.6%, remaining well above the standard clinically important difference threshold of 15% for oncology.
CONCLUSIONS: This post hoc analysis demonstrates that CPX-351 improved quality-adjusted survival, further supporting the clinical benefit in patients with newly diagnosed high-risk/secondary acute myeloid leukemia. Trial registration This trial was registered on September 28, 2012 at www.clinicaltrials.gov as NCT01696084 ( https://clinicaltrials.gov/ct2/show/NCT01696084 ) and is complete.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
---|---|
Enthalten in: |
Journal of hematology & oncology - 14(2021), 1 vom: 13. Juli, Seite 110 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Cortes, Jorge E [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 01.11.2021 Date Revised 01.11.2021 published: Electronic ClinicalTrials.gov: NCT01696084 Citation Status MEDLINE |
---|
doi: |
10.1186/s13045-021-01119-w |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM328025011 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM328025011 | ||
003 | DE-627 | ||
005 | 20231225202055.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s13045-021-01119-w |2 doi | |
028 | 5 | 2 | |a pubmed24n1093.xml |
035 | |a (DE-627)NLM328025011 | ||
035 | |a (NLM)34256819 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Cortes, Jorge E |e verfasserin |4 aut | |
245 | 1 | 0 | |a Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 01.11.2021 | ||
500 | |a Date Revised 01.11.2021 | ||
500 | |a published: Electronic | ||
500 | |a ClinicalTrials.gov: NCT01696084 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2021. The Author(s). | ||
520 | |a BACKGROUND: CPX-351 (United States: Vyxeos®; Europe: Vyxeos® Liposomal), a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio, is approved by the US FDA and the EMA for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes. In a pivotal phase 3 study that evaluated 309 patients aged 60 to 75 years with newly diagnosed high-risk/secondary acute myeloid leukemia, CPX-351 significantly improved median overall survival versus conventional 7 + 3 chemotherapy (cytarabine continuous infusion for 7 days plus daunorubicin for 3 days), with a comparable safety profile. A Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of the phase 3 study was performed to compare survival quality between patients receiving CPX-351 versus conventional 7 + 3 after 5 years of follow-up | ||
520 | |a METHODS: Patients were randomized 1:1 between December 20, 2012 and November 11, 2014 to receive induction with CPX-351 or 7 + 3. Survival time for each patient was partitioned into 3 health states: TOX (time with any grade 3 or 4 toxicity or prior to remission), TWiST (time in remission without relapse or grade 3 or 4 toxicity), and REL (time after relapse). Within each treatment arm, Q-TWiST was calculated by adding the mean time spent in each health state weighted by its respective quality-of-life, represented by health utility. The relative Q-TWiST gain, calculated as the difference in Q-TWiST between treatment arms divided by the mean survival of the 7 + 3 control arm, was determined in order to evaluate results in the context of other Q-TWiST analyses | ||
520 | |a RESULTS: The relative Q-TWiST gain with CPX-351 versus 7 + 3 was 53.6% in the base case scenario and 39.8% among responding patients. Across various sensitivity analyses, the relative Q-TWiST gains for CPX-351 ranged from 48.0 to 57.6%, remaining well above the standard clinically important difference threshold of 15% for oncology | ||
520 | |a CONCLUSIONS: This post hoc analysis demonstrates that CPX-351 improved quality-adjusted survival, further supporting the clinical benefit in patients with newly diagnosed high-risk/secondary acute myeloid leukemia. Trial registration This trial was registered on September 28, 2012 at www.clinicaltrials.gov as NCT01696084 ( https://clinicaltrials.gov/ct2/show/NCT01696084 ) and is complete | ||
650 | 4 | |a Clinical Trial, Phase III | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Multicenter Study | |
650 | 4 | |a Randomized Controlled Trial | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Acute myeloid leukemia | |
650 | 4 | |a Chemotherapy | |
650 | 4 | |a Quality-of-life | |
650 | 4 | |a Relapse | |
650 | 4 | |a Survival | |
650 | 4 | |a Toxicity | |
650 | 7 | |a Antineoplastic Agents |2 NLM | |
650 | 7 | |a CPX-351 |2 NLM | |
650 | 7 | |a Cytarabine |2 NLM | |
650 | 7 | |a 04079A1RDZ |2 NLM | |
650 | 7 | |a Daunorubicin |2 NLM | |
650 | 7 | |a ZS7284E0ZP |2 NLM | |
700 | 1 | |a Lin, Tara L |e verfasserin |4 aut | |
700 | 1 | |a Uy, Geoffrey L |e verfasserin |4 aut | |
700 | 1 | |a Ryan, Robert J |e verfasserin |4 aut | |
700 | 1 | |a Faderl, Stefan |e verfasserin |4 aut | |
700 | 1 | |a Lancet, Jeffrey E |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of hematology & oncology |d 2008 |g 14(2021), 1 vom: 13. Juli, Seite 110 |w (DE-627)NLM180433709 |x 1756-8722 |7 nnns |
773 | 1 | 8 | |g volume:14 |g year:2021 |g number:1 |g day:13 |g month:07 |g pages:110 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13045-021-01119-w |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 14 |j 2021 |e 1 |b 13 |c 07 |h 110 |